Thymosin Alpha-1 tracker
Educational reference for Thymosin Alpha-1. Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
2 h
Tmax
1 h
Category
peptide
Also known as: talpha1, zadaxin
> PLACEHOLDER — pending clinical review by licensed pharmacist. Thymosin alpha-1 is a 28-amino-acid peptide with immunomodulatory properties, acting through toll-like receptor (TLR) signalling and T-cell maturation pathways. It is approved as Zadaxin in several countries for hepatitis B and C adjunct therapy. Its plasma half-life is approximately 2 hours. In the research setting, it has been investigated for immune enhancement, vaccine adjuvancy, and chronic infection support. Patients using thymosin alpha-1 should track dosing schedules, injection sites, and any immune-related effects.
Mechanism
A synthetic peptide identical to a naturally occurring thymic peptide. In research it is associated with immunomodulatory activity, including effects on T-cell function and innate immune signaling.
Research summary
Studied for immune-related applications; a branded product (thymalfasin/Zadaxin) is approved in some countries for certain conditions such as chronic hepatitis B and as an adjuvant, though it is not FDA-approved in the United States for general use. Evidence varies by indication.
Dosing in the literature
Clinical studies used subcutaneous administration under trial or prescribing conditions. Specific regimens are individualized and outside the scope of this summary.
Reported side effects
Reported effects are generally mild in studies, including injection-site reactions. The safety profile varies by population and indication, and comprehensive long-term data are limited outside approved uses.
Stacking notes
In approved settings it has been studied as an adjuvant alongside other therapies; such combinations are clinical decisions. Unregulated products raise sourcing and purity concerns.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- Thymosin alpha-1 (thymalfasin) immunomodulation review · peer-reviewed review article (2018)search PubMed for thymosin alpha 1 thymalfasin
- Regulatory status note · FDA / international regulatory records (2020)approved in some countries; not FDA-approved in the US for general use; verify current status
References
- Thymosin alpha-1 clinical reviewDOI: 10.1111/j.1749-6632.2010.05566.x
Track Thymosin Alpha-1 in TrackPep
Reconstitution calculator, interactive body-map rotation, side-effect timeline, weight trends, and a private log — all in one place. Free to try.